Comparing a new drug to vosoritide for children with achondroplasia
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This trial tests a new medicine, BMN 333, against an existing one (vosoritide) to see if it helps children with achondroplasia grow. It's for kids who haven't used these treatments before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 11 years old (or up to 18 for Phase 3) and have achondroplasia confirmed by genetic testing
- Your bones must still be growing (open growth plates)
- You must be able to walk and stand without help
- You cannot have other causes of short stature like hypochondroplasia or Down syndrome
- You cannot have untreated thyroid problems, diabetes, inflammatory disease, or low vitamin D
- You cannot have used vosoritide or other growth treatments for achondroplasia in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called infigratinib to see if it can help young children with achondroplasia. It is for children under 3 years old who have a confirmed genetic diagnosis.
This trial studies how well infigratinib works and remains safe for children with achondroplasia. It includes children who already took infigratinib in a prior QED study, and some who are starting treatment for the first time.
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
This trial tests a new medicine (ABSK061) for children with achondroplasia, a common form of dwarfism. It aims to see if the drug is safe and can help with growth. Children age 3 to under 12 may qualify.
This trial tests a weekly injection called navepegritide for adolescents aged 12-18 with achondroplasia (a common form of dwarfism). The goal is to see if it can safely improve growth. You must have a genetic confirmation of achondroplasia and a historical height measurement from the past 6 to 15 months.
This trial tests a new weekly injection called TransCon CNP for infants with achondroplasia (the most common form of dwarfism). The goal is to see if it can help children grow better than a placebo (a shot with no medicine).
Hear when a new Achondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.